@karenjaninaz Can you share links or references to the studies you did showing Zometa is as effective as Reclast? Thank you if you can, but don't worry if you can't.

AI information comparing the two dosages is a bit confusing. I think the reason AI views Zometa as the "higher dosages" is because it is often administered more often when used with cancer patients, i.e., it may be given 2 or 3 times in a year as opposed to Reclast being given annually.

Bottom line, though, is that Zometa is 4 mg and Reclast is 5 mg. Hope I am not confusing people, but I have heard clinicians refer to Zometa being a higher dose than Reclast and it is not. It's only the scheduling of the infusions that would increase the dosage over time.

Here is what Google Ai says when comparing the two:

"Search Assist
Zometa and Reclast both contain the same active ingredient, zoledronic acid, but they are used for different conditions and dosages. Zometa is typically administered at higher doses for cancer-related issues, while Reclast is used for osteoporosis at lower doses, making direct comparisons of effectiveness at lower dosages not applicable.
cvbonehealth.com Mayo Clinic
Effectiveness of Zometa vs. Reclast
Zometa and Reclast both contain the same active ingredient, zoledronic acid, but they are used for different medical conditions and dosages.
Usage and Dosage
Medication Condition Treated Dosage Administration
Zometa Cancer-related issues (e.g., hypercalcemia, bone metastases) Higher doses, typically administered twice a year
Reclast Osteoporosis Lower doses, administered once a year
Comparison of Effectiveness
Zometa is designed for cancer patients and is given at higher doses to manage conditions related to bone health in cancer.
Reclast is specifically used for treating osteoporosis and is administered at lower doses.